Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.

Author: BankLeslie, BernsteinDavid, EpsteinMichael, KrishnanPreethi, LuceyMichael R, MartinezMarisol, NelsonDavid R, PockrosPaul J, PolepallyAkshanth R, PoordadFred, RavendhranNatarajan, ReindollarRobert, SedghiShahriar, TrinhRoger, UnnebrinkKristina

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This Phase 3 study evaluated the safety and efficacy of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) with low-dose ribavirin for 12 weeks in genotype 1a-infected patients without cirrhosis. The SVR12 rate was 89.5%. Although noninferiority to the weight-based ribavirin regimen was not met, this regimen offers an alternative for patients who cannot tolerate full-dose ribavirin.
Paper Details　
Original Abstract of the Article :
Patients infected with hepatitis C virus (HCV) treated with interferon-free direct-acting antivirals may still require ribavirin. However, ribavirin is associated with adverse events that can limit its use. This open-label, multicentre, Phase 3 study evaluated the safety and efficacy of ombitasvir/p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850388/

データ提供：米国国立医学図書館（NLM）

Treating Hepatitis C Genotype 1a: A New Perspective on Ribavirin

Hepatitis C virus (HCV) infection is a serious health concern, often requiring treatment with direct-acting antivirals (DAAs). This study examines the safety and efficacy of a combination therapy involving ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) with low-dose ribavirin for patients with genotype 1a HCV infection without cirrhosis. Think of this study as a camel caravan exploring a new route through the desert of HCV treatment.

The study involved 105 patients and found that the combination therapy achieved a sustained virologic response (SVR) in 89.5% of patients. This finding suggests that low-dose ribavirin could be a viable option for patients who may experience adverse effects from full-dose ribavirin. It's like discovering a new source of water in the desert, a safer alternative for camels who are sensitive to the harsh conditions.

Navigating the Challenges of Hepatitis C Treatment

The study provides valuable information for clinicians treating patients with genotype 1a HCV infection. The findings suggest that low-dose ribavirin in combination with OBV/PTV/r + DSV can be an effective and well-tolerated treatment option. This could be particularly beneficial for patients who are unable to tolerate full-dose ribavirin. It's like a camel caravan adapting its route based on the specific challenges of the desert terrain.

The Importance of Tailored Treatment Approaches

This research underscores the importance of personalized treatment approaches for HCV infection. While the combination therapy with low-dose ribavirin showed promising results, further research is needed to fully understand its efficacy and safety in different patient populations. It's like a camel caravan, choosing the most suitable path through the desert based on the individual camel's strength and endurance.

Dr. Camel's Conclusion

This study sheds light on a new approach to treating HCV genotype 1a infection. The combination therapy with low-dose ribavirin offers a potentially safer and effective option for patients who may experience side effects from full-dose ribavirin. Further research is needed to confirm its long-term efficacy and safety, but this study provides a promising path forward in the fight against HCV infection.

Date :
  1. Date Completed 2020-07-10
  2. Date Revised 2023-10-19
Further Info :

Pubmed ID

30980576

DOI: Digital Object Identifier

PMC6850388

Related Literature

Article Analysis
・Side Effects of ombitasvir paritaprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.